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INTRODUCTION 
  
Liver is a major site for various metabolic, synthetic and excretory 
functions. Cirrhosis of liver causes dearrangements in all functional aspects of 
liver. Cirrhosis can be due to alcohol, viral infections like hepatitis B and C, 
metabolic causes like non alcoholic fatty liver disease, Wilson’s disease, 
inherited diseases like hemochromatosis and autoimmune hepatitis .Bohan         
et al 
(1)
 described first about occurrence of diabetes in cirrhosis, which was later 
termed as hepatogenous diabetes by Megyesi et al
 (2)
. It is found that 57 % of 
patients with cirrhosis develop insulin resistance. Diabetes can occur in 14 % of 
patients and impaired glucose tolerance in 60- 80% of cirrhotics
(3,4)
. 
 
Insulin resistance is described as normal or elevated insulin producing 
attenuated insulin response
(5)
. Insulin resistance in cirrhosis can be due to 
impaired clearance of insulin by liver due to hepatocellular fibrosis or porto 
systemic shunting of insulin or impaired feedback regulation of insulin or 
increased pancreatic insulin secretion but the exact mechanism is still unclear. 
Many studies concluded that insulin resistance could be due to insulin receptor 
and post receptor defects resulting in hyperinsulinemia 
(6)
. Also in cirrhosis, 
portosystemic shunting causes decreased hepatic insulin and increased systemic 
circulating insulin.  
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Hyperinsulinemia thus occurred has multiple adverse effects on vascular 
bed.  Patients with cirrhosis and insulin resistance need regular glycemic 
monitoring as they may develop impaired glucose tolerance and diabetes in 
future which has definite clinical implications in the form of decrease response 
to treatment, rapid progression to fibrosis, hepatocellular carcinoma risk and 
increased complications due to cirrhosis. 
Lipid abnormalities have been reported in liver diseases. There are 
various results from different studies. This study is intended to find any relation 
between triglycerides and insulin resistance in euglycemic cirrhotics. 
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AIM & OBJECTIVES OF THE STUDY: 
 
1. To establish that cirrhosis of liver is an insulin resistant state. 
2. To establish the role of triglycerides in insulin resistance in patients with 
cirrhosis of liver 
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REVIEW OF LITERATURE 
LIVER: 
Liver is the largest gland in our body performing various secretory, 
excretory and metabolic functions. It weighs about 1400-1600 gram
(7)
, 
constituting 2.5% of body weight. It extends from right fifth intercostal space 
along midclavicular line upto right costal margin. The size is about 12-15 cm in 
the coronal section and 15-20 cm in the transverse axis. The microarchitecture 
of liver can be discussed as lobular architecture and acinar model. 
PICTURE 1: Microarchitecture of liver
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BLOOD SUPPLY: 
Liver receives 75% of its blood supply though portal vein and 25% from 
hepatic artery. The vessels enter liver via porta hepatis and they branch within 
the liver substance to form portal triad 
(10,11)
  which includes branches of hepatic 
artery, portal vein and bile duct. 
 
PICTURE 2: Portal triad –portal vein, bile duct and hepatic artery 
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FUNCTIONS OF LIVER:  
METABOLIC : 
The liver is the final resort of all metabolic functions governing 
carbohydrate, protein and lipid metabolism in multiple ways.  
 The key function in glucose metabolism is storage of glucose in the form 
of glycogen in well fed state and performing glycogenolysis and 
gluconeogenesis in fasting state. Glycogen stored in liver is the major 
source of energy for rapidly glucose requiring tissues like RBC, retina, 
renal medulla and brain. Glycogen stores in liver can supply glucose upto  
2 days before gluconeogenesis occurs. Hence it is not uncommon to get 
hypoglycemia in chronic liver disease patients. 
 Fatty acid undergoes beta oxidation forming acetyl coenzyme A which   
enters citric acid cycle and gives energy. 
 Liver helps in protein metabolism in formation of urea from ammonia and 
deamination of amino acids. 
 The synthesis of cholesterol, phospholipids and various lipoproteins and 
plasma proteins occur in liver. 
 Apolipoproteins are proteins synthesised by liver. It combines with 
triglycerides,cholesterol, cholesterol esters to form lipoproteins. These 
lipoproteins mediate transport of lipids from liver to tissues and tissues to 
liver and other organs. Lipoproteins are classifieds according to their 
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relative density which is inversely proportional to the size. In the order of 
increasing density they are: 
 Chylomicrons 
 Very low density lipoproteins 
 Intermediate lipoproteins 
 Low density lipoproteins  
 High density lipoproteins 
CIRRHOSIS OF LIVER: 
Cirrhosis is derived from scirrhus a Greek word, meaning orange or 
tawny. Cirrhosis, a final pathway for a wide variety of chronic liver disease, is a 
pathologic entity defined as diffuse hepatic fibrosis with the replacement of the 
normal liver architecture by nodules 
(12)
. 
The three important morphological features described pathologically 
includes: 
   
•
     
Bridging fibrous septa 
Fibrous strands may occur between portal tracts and between portal tract and 
terminal hepatic vein. Following hepatocellular necrosis, healing occurs by 
deposition of collagen followed by remodelling .Fibrosis is the key feature 
of cirrhosis indicating progressive damage to the liver. 
19 
 
   
•
  
Parenchymal nodules: 
 Nodules are due to regeneration of hepatocytes surrounded by fibrosis. 
   
•
     
Architectural disruption of the entire liver is due to diffuse parenchymal 
injury and fibrosis. 
Pathologically it can be micronodular or macronodular depending on the 
size. 
Clinically it can be broadly classified as compensated cirrhosis or 
decompensated. The development of jaundice, hepatic encephalopathy, 
bleeding from varices, ascites and hepatocellular carcinoma indicates 
decompensation. Four clinical stages have been proposed. Stage 1 and 2 are 
compensated cirrhosis. Stage 3 and 4 are decompensated cirrhosis. 
 Stage 1: Absence of varices and ascites 
Stage 2: Presence of varices without bleeding and absence of ascites 
Stage 3: Ascites with or without esophageal varices 
Stage 4: Variceal bleeding with or without ascites  
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ETIOLOGY OF CIRRHOSIS 
VIRAL Hepatitis B virus 
Hepatitis C virus 
TOXIC Alcohol  
Arsenic 
AUTOIMMUNE Autoimmune hepatitis 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
METABOLIC Alpha 1 antitrypsin deficiency 
Hemochromatosis 
Glycogen storage diseases 
Wilson s disease 
Non alcoholic fatty liver disease 
Galactosemia  
BILIARY Atresia 
Stone  
Tumor 
VASCULAR Budd chiari syndrome 
Cardiac cirrhosis 
GENETIC Cystic fibrosis 
Liposomal acid lipase deficiency 
21 
 
PATHOGENESIS 
                     Fibrosis is the healing process to any injury in our body. 
Following an injury to liver, as a process of normal wound healing, there 
may be abnormal matrix deposition which differs both qualitatively and 
quantitatively
(14)
: This happens irrespective of the type of insult
(15)
. The key 
event in overall pathogenesis is sub endothelial collagen deposition in space 
of Disse leading to disruption of normal sinusoidal function
(16)
. 
                     Following liver injury, there are various alterations in the 
normal extracellular matrix leading to upregulation of many cellular 
receptors which mediate interaction between inflammatory cells and 
endothelium. Increase in expression of fibronectin in the cells is the earliest 
response which creates an environment for fibrosis. The hepatic stellate cells 
in the subendothelial space are also termed as Ito cells, perisinusoidal cells, 
fat storing cells are the main sources of extracellular matrix
(17)
. Under 
various cytokines from inflammatory cells, they assume phenotypic 
resemblance to myofibroblasts with contractile property. Stellate cell 
activation refers to “the transition from a quiescent vitamin A-rich cell to a 
highly fibrogenic cell characterized morphologically by the enlargement of 
rough endoplasmic reticulum, diminution of vitamin A droplets, ruffled 
nuclear membrane, appearance of contractile filaments, and proliferation”. 
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PICTURE 3: liver fibrosis 
                         Due to fibrosis, vascular channels are contracted and liver 
becomes small with severely compromised blood to hepatocytes. Finally 
interaction between hepatocytes and plasma in secreting various substances 
is severely impaired. Jaundice occurs due to disruption of portal tracts by 
fibrosis. 
 
        PICTURE 4:overview of pathogenesis and reversal of fibrosis 
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Reversal of fibrosis occurs due to myofibroblast deactivation, apoptosis or 
senescence. Matrix proteases can also achieve resolution of fibrosis. 
 
 
 
 
PICTURE 5: Showing fibrosis in the portal tract by Mason Trichrome 
stain, expansion of portal tract, but surrounding acinar parenchyma is 
normal. 
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CLINICAL MANIFESTATIONS: 
        Although there are many causes of cirrhosis, the clinical features
(18)
 that 
come to light are features of hepatocellular failure or complications of 
cirrhosis. 
PICTURE 6: Clinical features of liver cell failure
 
 
 
25 
 
ASCITES:  It is due to portal hypertension 
HEMATEMESIS/ MALENA: Due to bleeding from varices 
ALTERED CONSCIOUS LEVEL: It occurs because of hepatic 
encephalopathy. 
EASY FATIGUABILITY: It is due to wasting, anorexia and decreased 
metabolism. 
JAUNDICE:  Alteration in bilirubin metabolism causes jaundice. 
ABDOMINAL PAIN: Abdominal pain along with increasing distension is 
due to spontaneous bacterial peritonitis. 
 FEVER AND INFECTION : 
           About a third of them have low grade continuous fever due  to 
elevated cytokines in liver disease. Normally portal filters and hepatic 
system are bacteriologically sterile but when extensive collaterals occurs gut 
bacteria gain access to systemic circulation. Common infections include 
spontaneous bacterial peritonitis, pneumonia and urinary tract infection.  
FETOR HEPATICUS: 
    It is a sweetish slightly faecal smell in the breath of patients with 
hepatocellular failure. It is presumed due to elevated mercaptans from 
impaired methionine demethylation. 
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VASCULAR SPIDERS: 
                      Spider naevi or spider angiomata is a central feeding arteriole 
with surrounding radiating vessels..  
LIVER PALMS: 
                    There is warmth and redness in palms especially in hypothenar 
and thenar eminences and also in soles. 
WHITE NAILS: 
                   It is the opacity of nails occuring especially in thumb and index 
finger bilaterally. 
Though the etiology for white nails and palmar erythema is not known 
clearly it can be due to elevated estrogens levels.  
COAGULOPATHY:  
                              Liver is the principal site of production of all clotting 
factors like vitamin K dependent clotting factors like 2,7,9,10 and factor 5, 
12, 13 except Von Willebrand factor. Coagulopathy in liver diseases can be 
due to the following reasons: 
 Decreased synthesis of clotting factors 
 Vitamin K malabsorption / deficiency due to antibiotics, drugs and 
cholestasis 
 Decreased production of inhibitors of clotting 
 Hyperfibrinolysis 
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 Decreased clearance of activated clotting factors by liver 
 Increased risk of DIC in the setting of sepsis  
 Platelets number is decreased due to hypersplenism, intrinsic defect 
and reduced synthesis due to reduced availability of arachidonic acid 
for prostaglandin synthesis. 
ENDOCRINE CHANGES: 
There is impotence, loss of libido, gynecomastia and loss of secondary 
sexual characters in male leading to feminization particularly in alcoholics. 
In female, there is ovulatory failure, infertility and erratic menstruations. All 
are proposed to be due to increase in estrogen receptors and their sensitivity 
in cirrhotics. 
PROGNOSTIC SCORES: 
                            Poor prognosis in cirrhosis is indicated by prolonged 
prothrombin time, ascites, advanced age, gastrointestinal bleeding, high 
serum bilirubin and alkaline phosphatase. Liver transplantation mandatates 
accurate scores to assess prognosis so that surgery can be done at right time 
CHILD TURCOTT PUGH SCORE(CTP) score: 
                   It depends on jaundice, ascites, encephalopathy,serum albumin 
con- centration and nutrition.It gives a good short - term prognostic guide. 
Prothrombin time can be used rather than nutritional status called as Child – 
Pugh modification and individual features are scored by severity. The 
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total score classifies patients into grade A, B or C. 
Measure 1 2 3  
Total bilirubin 
(mg/dl) 
<2 2-3 >3  
Serum 
albumin(d/dl) 
>3.5 2.8-3.5 <2.8  
Prolongation of 
prothrombin time 
<4 4-6 >6  
Ascites None Mild Moderate- 
severe 
 
Hepatic 
encephalopathy 
None Grade 1-2 or 
suppressed by 
medication 
Grade 3-4 
Refractory 
 
 
 
 
Scores   5-6 :  child A 
             7-9  : child B 
        10-15   : child C 
 
MELD score: 
                       It is Model for End stage Liver Disease and it was originally 
developed in Mayo clinic. 
MELD uses the patient's values for serum bilirubin, serum creatinine, and 
the international normalized ratio for prothrombin time (INR) to predict 
survival.  
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It is calculated according to the following formula:  
MELD = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 
9.57×ln[serum creatinine (mg/dL)] + 6.43× aetiology (0: cholestatic 
or alcoholic, 1: otherwise) 
 In interpreting the MELD Score in hospitalized patients, the 3 month 
mortality is:   
 40 or more — 71.3% mortality 
 30–39 — 52.6% mortality 
 20–29 — 19.6% mortality 
 10–19 — 6.0% mortality 
 <9 — 1.9% mortality 
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ALCOHOLIC CIRRHOSIS 
                  Alcohol, is the most important etiology for development of liver 
disease. The spectrum of disease ranges from mild fatty accumulation 
through steatohepatitis to frank cirrhosis. But not necessarily disease 
evolution occurs through stages, even multiple stages can be present in any 
patient. Fatty liver and steatohepatitis can be reverted if patient abstains 
from alcohol intake. 
 
PICTURE 7: Stages of Alcoholic liver disease 
RISK FACTORS 
(20-22)
: 
 Amount of alcohol: Alcohol consumption of about 60-80g/day in 
men and 20-40 g/day in women for 20 years  
 Type of alcohol 
 Sex : Women more sensitive due to higher body fat and reduced 
gastric alcohol dehydrogenase 
 Presence of malnutrition 
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 Binge drinking  
 Polymorphism of genes involved in metabolism of alcohol 
 Coexistent hepatitis C virus infection and obesity 
PATHOGENESIS: 
                                  Alcohol is metabolised by alcohol dehydrogenase, 
microsomal ethanol oxidising system( MEOS) CYP2E1 and little by 
peroxisomal catalase 
(23)
. Acetaldehyde combines with proteins to form 
protein adducts which interfers with normal biological processes like 
microtubular formation, various enzyme activities and protein synthesis, 
trafficking and secretion. Due to hepatocyte injury by reactive oxygen 
species, kupffer cells get activated which may initiate fibrosis by 
programming stellate cells to fibroblasts through various proinflammatory 
mediators. 
PATHOLOGY: 
                During initial stages, it is yellow tan, enlarged and fatty weighing 
more than 2 kilograms. Later it becomes small, shrunken, fibrotic and 
weight goes less than 1 kilogram. Cirrhosis initially is around the central 
vein termed as Lennaec cirrhosis. The fibrous septa is seen between portal 
tract-portal tract and from central vein to portal tract. At the end stage, it 
resembles like other causes of cirrhosis. 
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PICTURE 8 shows 1. Inflammatory cell infiltration 2. Mallory bodies ( 
eosinophilic) surrounded by fibrosis. 
 
 
PICTURE 9: Diffuse nodularity with green tinge due to bile stasis, 
hepatocellular carcinoma seen from the right lobe 
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PICTURE 10: Microscopic picture shows nodules surrounded by fibrosis 
 
VIRAL HEPATITIS  
                      Hepatitis B virus is a DNA virus belonging to hepadnaviridae 
family. Infection of HBV virus causes chronicity occurs in 2 %- 5% of 
cases. About one third of them develop cirrhosis and related complications. 
Hepatitis C virus is a single stranded RNA virus belonging to flaviviridae. 
About 3% of people are infected globally.  
                                            Hepatitis C virus is known for its chronicity and 
it progresses to cirrhosis over a period of 20 years. There are few other 
factors like alcoholic intake, coexistent hepatitis B infection, 
immunosuppression, insulin resistance, tobacco use and white race influence 
the disease progression to fibrosis.  
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PICTURE 11: Natural history of hepatitis C virus 
 
 
PICTURE 12: Chronic hepatitis 
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NON ALCOHOLIC FATTY LIVER DISEASE 
             Nonalcoholic fatty liver disease (NAFLD)
(26)
  indicates the presence 
of fatty infiltration of the liver and is defined as fat exceeding 5–10% of  
weight and frequently taken as >5–10% macrosteatotic 
hepatocytes in biopsy specimens.  
     In 1980, the disease was reported from Mayo clinic due to the 
resemblance with alcoholic cirrhosis. The disease is directly related to the 
obesity prevelance and severity in the population. It is considered as the 
hepatic manifestation of metabolic syndrome. The spectrum can be 
macrovesicular steatosis, hepatitis and finally cirrhosis. Patients are 
diagnosed many times due to incidental findings of elevated liver enzymes. 
Symptoms can be right upper quadrant pain and fatigue. 
                           A detailed alcohol history is important before diagnosis. All 
other etiologies have to be ruled out. Finally liver biopsy gives picture like 
alcoholic cirrhosis. Management is weight loss and exercise.Anti oxidants 
like vitamin E and thiazolidienediones are approved for treatment. Multiple 
trials are ongoing to find newer treatment options in managing NAFLD.  
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WILSON’S DISEASE 
                    Wilson’s disease is an autosomal recessive disease due to 
ATP7B gene mutation in chromosome 13. It causes impaired biliary 
excretion of copper and hence hepatic accumulation leading to toxicity.  It 
occurs in fourth to fifth decade
(27,28)
. It may present as hepatitis or cirrhosis 
with elevated transaminases with or without jaundice. Other features are 
dystonia, incoordination and tremors can occur due to deposition of copper 
in basal ganglia, psychiatric abnormality like crying, temper tantrums, 
arthritis, spontaneous abortions in female, Fanconi syndrome, 
nephrolithiasis and osteoarthritis. In eye, sunflower cataract and Kayser 
Fleischer rings can be seen. 
                                         Diagnosis can be done by 24 hour urinary copper 
and liver biopsy. Serum cerruloplasmin should not be used to make 
diagnosis as it is normal in 10% of patients. Treatment options are 
penicillamine, zinc, tetrathiomolybdate, trientine and liver transplantation. If 
there is severe decompensation, transplantation is the treatment. In 
pregnancy, presymptomatic, pediatric and for maintenance therapy, zinc is 
the treatment of choice. 
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HEREDITARY HEMOCHROMATOSIS 
                                
                      Initially though it was thought to be a haematological disease, 
later it was found to be a disorder of iron metabolism. In 1996, HFE gene 
mutations (C282y and H63D) in short arm of chromosome 6 was found to 
be the cause for hereditary hemochromatosis 
(29)
. Secondary iron overload 
can present with same features. Symptoms can be myalgia, arthralgia, 
anorexia or features of chronic liver disease.  Features due to iron overload 
in various organs like cardiomyopathy, arrhythmias, skin 
hyperpigmentation, diabetes, arthritis can be there. 
 
                                       When the disease is suspected based on clinical 
features, family history or anything, transferrin saturation or ferritin level 
should be seen. Genetic testing is mandatory to confirm diagnosis. 
Treatment is aimed at maintaining iron levels by maintenance phlebotomy 
and treating complications of cirrhosis. 
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ALPHA 1 ANTITYPSIN DEFICIENCY 
                              Alpha 1 antitrypsin deficiency is another metabolic cause 
for cirrhosis. Though the exact mechanism is not known, it is postulated that 
structural aberration, misfolding and accumulation of proteins within 
endoplasmic reticulum can play a role. The disease has to be suspected in 
any cirrhosis with portal hypertension or hepatocellular carcinoma when all 
the infections are ruled out. Histologically liver biopsy shows characteristic 
periodic acid Schiff positive diastase resistant globules which are 
polymerized alpha 1 antitrypsin protein.  
 
INDIAN CHILDHOOD CIRRHOSIS 
                   A serious liver disease affecting infants and young children was 
first reported in a paediatric meet conducted in Kolkata. It was initially 
termed as infantile cirrhosis or infantile biliary cirrhosis. There are specific 
histopathological changes in the established stages of disease. It is found 
that liver contain excess stainable copper far in excess than Wilson’s 
disease.  
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CRYPTOGENIC CIRRHOSIS 
                     The term cirrhosis of unknown etiology has started declining 
after discovery of hepatitis B virus in 1965, hepatitis D virus and hepatitis C 
virus in 1989. After establishing criteria to diagnose autoimmune hepatitis 
and Non Alcoholic fatty liver disease, incidence of cryptogenic cirrhosis had 
still declined. To make it short it is a vanishing type of cirrhosis. 
 
INVESTIGATIONS  
 Hemogram:  
                      Anemia can due to nutritional cause, variceal bleeding, 
direct suppressive effect of alcohol on bone marrow. 
Thrombocytopenia is due to hypersplenism and decreased 
thrombopoietin production from liver. 
 RENAL PROFILE: 
                   Elevated renal parameters can be seen in hepatorenal 
syndrome, sepsis and prerenal acute kidney injury in the setting of 
diuretics and bleeding.  
 CHEST X RAY: To rule out hepatic hydrothorax 
 LIVER FUNCTION TESTS: 
                    Elevated bilirubin in the setting of cirrhosis signifies 
advanced disease. Ratio of AST/ALT > 2 is suggestive of alcoholic 
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hepatitis. ALT is more elevated in viral etiology. If alkaline phosphatase 
is elevated hepatocellular carcinoma has to be ruled out. Low alkaline 
phosphatase should prompt us evaluate for Wilson s disease 
 SERUM ALBUMIN:  In cirrhosis, the levels are low and it is 
correlated well with disease severity and survival of patients. 
 COAGULATION PROFILE 
 ULTRASOUND ABDOMEN: To see the liver echotexture, size, 
presence of free fluid, collaterals in portosystemic areas and 
screening for hepatocellular carcinoma. 
 PORTAL VEIN DOPPLER: To look for the size of portal vein, 
dilation and flow which may be static or reversed.  
 ASCITIC FLUID ANALYSIS: 
Elevated leucocytes with PMN> 250 cells/cu.mm confirms the 
diagnosis of spontaneous bacterial peritonitis. 
Serum ascitic albumin gradient (SAAG) of  >1.1 is 97% specific for  
diagnosing ascites due to portal hypertension. 
In cirrhosis, ascitic fluid protein will be < 2.5mg/dl. 
 VIRAL MARKERS: HBsAg and anti HCV to be done to rule out 
viral etiology. 
  SLIT LAMP EXAMINATION : To rule out KF ring 
 SERUM CERRULOPLASMIN AND 24 HOUR URINE COPPER 
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 AUTOIMMUNE WORK UP:  ANA, LKM1 ,SMA, SLA 
 PRIMARY BILIARY CIRRHOSIS: Anti mitochondrial antibody 
against pyruvate dehydrogenase complex 
  GENETIC ANALYSIS: for hereditary hemochromatosis 
  NON INVASIVE METHODS TO MEASURE FIBROSIS:  
                         FIBROSCAN- Transient Elastography 
                         FIBROMETER 
 UPPER GI ENDOSCOPY:  Screening upper GI endoscopy should be 
done for all patients to rule out esophageal varices, fundic varices and 
gastropathy. 
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COMPLICATIONS 
PORTAL HYPERTENSION 
                    It is defined as hepatic venous pressure gradient more than 
5mmHg.There is selective intrahepatic vasoconstriction and splanchnic 
vasodilatation in cirrhosis which is behind all the clinical features. The 
increased portal pressure is due to altered vasoactive factors, mechanical 
factors like capillarization of sinusoids, narrowing of vessels due to fibrosis 
and nodules disrupting the architecture. The increased portal pressure is 
decompressed into systemic circulation at the sites of portosystemic 
anastomosis forming collaterals. 
                          The classic features include ascites, varices and 
splenomegaly. Management of portal hypertension is aimed at decreasing 
splanchnic blood flow through vasopressin analogues and beta blockers. 
Endoscopic therapy is aimed at prevention of variceal bleeding, controlling 
acute bleeding episode and for rebleeding prevention.  
ASCITES 
                    In cirrhosis, there is elevated nitric oxide in splanchnic 
circulation which causes pooling of blood in splanchnic system  and hence 
decreased effective circulatory volume. It is perceived by kidneys as 
hypovolemia leading to activation of renin angiotensin system causing salt 
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and water retention 
(34)
. Patient with ascites experiencing sudden increase 
should alarm the physician in ruling out hepatocellular carcinoma. 
Patients should be treated with salt restriction, fluid restriction if there is 
associated hyponatremia and diuretics like aldosterone antagonists and loop 
diuretics in a fixed combination of 4:1. 
 
SPONTANEOUS BACTERIAL PERITONITIS 
                     Bacteria in gut may translocate and reach mesenteric lymph 
nodes and infect the ascitic fluid. When the opsonin activity is poor, it 
results in spontaneous bacterial peritonitis 
(35)
. When the opsonin activity is 
moderate it cuases CNNA (culture negative non neutrocytic ascites) and 
when it is good it causes sterile non neutrocytic ascites. Management 
includes antibiotics like third generation cephalosporins / fluroquinolones 
along with albumin to prevent hepatorenal syndrome. 
 
RENAL FAILURE IN CIRRHOSIS  
          Acute renal dysfunction occurs in about  15% -25% of patients who 
are hospitalized with cirrhosis. It occurs in about 30 % of patients with any 
infection, 25% in alcoholic hepatitis and in 10% who undergoes large 
volume paracentesis
(36,37)
.  
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HEPATORENAL SYNDROME 
              HRS is classified into two types- type 1 and type 2. Type 1 is 
rapidly progressive renal failure of creatinine > 2.5 mg/dl in a period of less 
than 2 weeks. Type 2 HRS is slowly progressive characterized by creatinine 
< 2.5mg/dl
(38). 
 DIAGNOSTIC CRITERIA:  It is defined by International Ascites club as 
follows: 
1. Cirrhosis with ascites 
2. Serum creatinine more than or equal to 1.5 mg/dl 
3. No or insufficient improvement in serum creatinine level 48 hours 
after diuretic withdrawal and adequate volume expansion with  IV 
albumin 
4. Absence of shock 
5. No evidence of recent use of nephrotoxic agents 
6.Absence of intrinsic renal disease 
                     HRS can be prevented by avoiding injudicious volume 
depletion like large volume paracentesis, diuretics and lactulose therapy, 
prompt diagnosis of any infection and SBP prophylaxis. Treatment of HRS 
includes management of any infection, avoiding any nephrotoxic agents, 
vasopressors like terlipressin, midodrine and octreotide or nor epinephrine. 
The ultimate goal is preparing the patient for liver transplantation. 
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HEPATIC ENCEPHALOPATHY: 
                       The term includes “wide array of transient and neurologic and 
psychiatric manifestations usually in patients with chronic liver disease and 
portal hypertension” (39). 
                        In cirrhosis lot of vasoactive mediators lead to splanchnic 
vasodilatation, impaired hepatic function and alteration in blood brain 
barrier. There is impaired ammonia clearance by liver through urea cycle. 
Portosystemic shunting causes elevated serum ammonia. It finally leads to 
brain swelling, astrocyte swelling and altered neurotransmitters like 
increased GABA
(40)
. There are many scoring systems to grade hepatic 
encephalopathy of which most accepted one is West haven criteria.
 
                        An elevated level of serum ammonia in a patient with 
impaired consciousness and cirrhosis may suggest hepatic encephalopathy 
(41)
. False positives include GI bleeding, drugs like valproic acid, alcohol and 
diuretics. Management is aimed at correcting the precipitating factors 
antibiotics and laxatives. The one and three year survival rate after hepatic 
encephalopathy are 42% and 23 % respectively without liver transplantation. 
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HEPATOPULMONARY AND PORTOPULMONARY 
HYPERTENSION 
                             Cirrhosis with portal hypertension alters multiple vascular 
bed. Two defined diseases in pulmonary system includes hepatopulmonary 
and portopulmonary hypertension.   
HEPATOPULMONARY HYPERTENSION 
                          It is defined as “widened arterial alveolar oxygen gradient in 
room air in the presence or absence of hypoxemia”. In cirrhosis the 
inflammatory mediators particularly NO and TNFα are increased in the 
pulmonary bed which cause vasodilation and angiogenesis leading to 
hypoxemia. It is found in 30% of patients with cirrhosis evaluated for liver 
transplantation. Clinical features platypnea, progressive dyspnea, cyanosis 
and clubbing. Diagnosis is made by contrast echocardiography using 
agitated saline.  Long term oxygen lowers hypoxemia and pentoxifylline has 
been studied in multiple trials.  
 
PORTOPULMONARY HYPERTENSION 
                     It occurs due to vasoconstriction and remodelling of resistance 
vessels increasing pulmonary artery pressure. Though exact 
pathophysiology is not known, elevated endothelin levels are proposed. 
Management options include vasodilators like prostaglandins, endothelin 
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receptor antagonists like bosentan, ambrisentan and phosphodiesterase 
inhibitors like sildenafil. 
HEPATOCELLULAR CARCINOMA 
                            It is the most common primary malignancy of liver 
(43)
. It 
occurs in liver with cirrhosis due to any cause like alcohol, hepatitis B and 
hepatitis C and less commonly with hereditary hemochromatosis, Wilson’s 
disease, non-alcoholic fatty liver disease, alpha 1 antitrypsin deficiency and 
autoimmune hepatitis. 5year cumulative risk of getting HCC in the setting of 
cirrhosis due to above mentioned causes is 5-30% which is maximal with 
hepatitis C and decompensation.  
Worldwide it is hepatitis B contributing to 50% of cases 
and almost all of childhood cases are due to hepatitis B due to the risk of 
perinatal transmission in developing countries. Though hepatitis B virus can 
lead to HCC without cirrhosis, about 90% of cases are related to cirrhosis 
only. 
                              The estimated risk of HCC with hepatitis C virus  is 15- 
20 times than with those who are not infected. The risk is maximum with 
advanced hepatic fibrosis and cirrhosis
 (44)
. Symptoms produced are of little 
value like dyspepsia, loss of apetite and weight loss. In patients with 
cirrhosis it may occur with decompensation like worsening of hepatic 
encephalopathy and increasing ascites.                             
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 Screening is reasonable in Asian men >40 years, Asian 
women > 50 years, family history of hepatocellular carcinoma and high viral 
load. The screening test of choice would be an ultrasound. Nodules of size 
upto 1cm needs 3-6monthly screening with ultrasound. Nodules of size 1-2 
cm should be evaluated further. Alpha fetoprotein >200 ng/ml is suggestive 
and >400ng/ ml  is very likely for hepatocellular carcinoma.  
                       The diagnostic modality of choice is dynamic CT scanning 
(45,46)
. Various staging systems are available in which Barcelona clinic 
staging system (BCLC) is widely used. Treatment options include liver 
transplantation, transarterial chemoembolization (TACE), radiofrequency 
ablation and systemic therapy with PDGF inhibitor sorafenib. In a 
randomnized trial it had a survival advantage of 10.7 month survival 
compared to 7.9 month for placebo. The drug is approved by FDA to treat 
CTP A and unresectable hepatocellular carcinoma. 
                                The best strategy to prevent this disease is avoiding  
high rish behaviours, vaccination for hepatitis B virus and treatment of 
chronic hepatitis B and C. Nowadays  national vaccination schedules have 
significantly reduced the incidence of HCC. There is moderately strong 
evidence for using antivirals for both hepatitis B and hepatitis C virus may 
significantly reduce but does not eliminate the risk of hepatocellular 
carcinoma. According  to NEJM, several non randomized and one 
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randomized controlled study patients with HCV infection but without 
cirrhosis who are treated with interferon based regimen showed reduced 
incidence of hepatocellular carcinoma.  
INSULIN:  
               Insulin is a polypeptide anabolic hormone synthesised in rough 
endoplasmic reticulum of beta pancreatic cells. It exerts it physiological role 
in maintaining glucose homeostasis and cell mitosis. It is transported to 
golgi apparatus for package, then to plasma membrane where release occurs 
by exocytosis. It has two chains A chain and B chain linked by two 
disulphide bridges. 
INSULIN RECEPTOR:  
                      It is a tetramer with two alpha and beta subunits belonging to 
tyrosine kinase receptor family. It is also the receptor for insulin like growth 
factor and insulin receptor- related receptor ( IRR).The gene for insulin 
receptor is located in chromosome 9
(47)
. The two α subunits are located 
outside the plasma membrane and β subunits span the membrane. The 
tyrosine kinase activity is intrinsic to β subunit which is inhibited by α 
subunit. Removal of α unit or binding of insulin to α sub unit may cause 
derepression and cause enhanced tyrosine kinase.The knowledge of insulin 
receptors are evolutionarily very ancient described in drosophilia and 
porifera. 
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                         Binding of insulin to insulin receptor activates it through 
phosphorylation and then various insulin receptor substrates (IRS). It has 
multiple signal pathways like phosphatidyl inositol 3 kinase /Akt kinase and 
protein kinase pathway 
(48)
.  
                           Insulin receptor substrates are cytoplasmic proteins that 
send signals from insulin receptor to initiate variety of cellular response. IRS 
1 and IRS 2 are ubiquitous in our body 
(49)
, involved in glucose metabolism 
and insulin mediated mitogenesis .Also reported that IRS 2 is more 
important in insulin glucose signalling and metabolism. AKt promotes 
glycogen synthesis and supresses gluconeogenesis. In striated muscle, the 
same receptor causes translocation of GLUT 4 to plasma membrane which 
facilitates uptake of glucose into cells. A negative feedback emanating from 
activation of AKt/ phosphoinositol pathway cause termination of IRS 
substrate action. 
                     Constant supply of glucose to vital organs like brain, RBC s 
and liver can occur without insulin action but adipose tissue and skeletal 
muscle can utilise glucose only under the action of insulin through GLUT 4 
receptors. After a meal, efflux of GLUT 4 receptors into the membrane 
occurs to allow influx of glucose into the cell. In well fed state, insulin 
promotes glycogen storage in liver and storage of fatty acids in the form of 
triglycerides through of activation of lipoprotein lipase. 
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INSULIN RESISTANCE 
                       Insulin resistance is defined as “the inability of exogenous or 
endogenous insulin to increase glucose uptake and utilization to the level 
occurring in normal population”. 
EPIDEMIOLOGY: 
                       Insulin resistance is found in all the races with clustering of 
cases among whites. The increased risk of cardiovascular disease among 
insulin resistant individuals is higher among middle aged individuals though 
risk increases with age. Acanthosis nigricans, a common physical finding in 
insulin resistance, though found in all races is reportedly high among 
Hispanics and Blacks. 
                       Action of insulin at the insulin receptors produce two major 
functions like one in glucose metabolism and other in cell mitosis. In 
diabetes, resistance is present to glucose metabolism but cell growth is 
preserved. Insulin resistance occurs in the ligand –receptor- response 
pathway which can be at the insulin receptor level or at insulin response 
substrates. Therefore compensatory hyperinsulinemia occurs to maintain the 
glucose level in blood. Some defects are being demonstrated with reduced 
substrates or phosphorylation by these residues. Insulin resistance is a 
significant phenomenon that causes impaired glucose tolerance and diabetes. 
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                       Insulin sensitivity and insulin release are reciprocally related. 
Thus, insulin resistance results in increased release of insulin to normal lipid 
and glucose homeostasis. Some mediators signal the pancreatic beta cells in 
response to insulin resistance but failure of those to adapt significantly may 
cause inappropriate insulin release, IGT and may be diabetes. Inflammation 
and cytokines play a role in insulin resistance in metabolic syndrome. It is 
supported by increased C- reactive protein suggesting chronic low grade 
inflammation. In many studies, they have found increased CRP levels may 
predict cardiovascular disease and diabetes in future. 
CAUSES OF INSULIN RESISTANCE: 
 Prereceptor causes of insulin resistance include abnormal insulin 
mutations and anti-insulin antibodies. 
 Receptor causes include the following: 
Decreased number of receptors - failure to activate tyrosine kinase 
Reduced binding of insulin 
Insulin receptor mutations 
Insulin receptor–blocking antibodies 
 Post receptor causes include defective signal transduction and 
mutations of GLUT4. 
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CONDITIONS ASSOCIATED: 
 It is a well-established in conditions like obesity, hepatitis C virus, 
metabolic syndrome, accelerated atherosclerosis. 
 Aging: due to reduced GLUT 4 receptors 
 Increased production of insulin antagonists: Cushing syndrome, 
acromegaly, and stress states, such as trauma, surgery, diabetes 
ketoacidosis and severe infection. 
 Medications: glucocorticoids, cyclosporine 
 Sodium:  High sodium intake has been associated with increased 
glucocorticoid production and insulin resistance.  
 Anti HIV therapy: Nucleoside analogues are associated. 
 Insulin therapy: Low titre immunoglobulins are present in patients 
who take insulin which may cause prereceptor insulin resistance. 
 
            Obesity is the most common cause of insulin resistance and it is is 
associated mainly with postreceptor abnormality and also with a decreased 
number of insulin receptors. 
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INSULIN RESISTANCE IN CIRRHOSIS: 
                         Bohan et al 
(1)
 described association between liver cirrhosis 
and diabetes, whereas Megyesi et al 
(2)
 termed it as hepatogenous diabetes 
where 57% of patients with cirrhosis are found to have insulin resistance. 
Hepatitis C virus, Non Alcoholic fatty liver disease and autoimmune 
hepatitis are found to be well associated with insulin resistance.  
 
                          In AIIMS, Jain et al assessed glucose tolerance in 
euglycemic cirrhotics using insulin suppression test (Modified Hirano s 
method)
(51)
. They found that cirrhotics had higher 90 min and 120 min 
plasma glucose and 120 min serum insulin suggesting higher postprandial 
glucose and insulin. They have higher than normal insulin to produce 
normal glucose homeostasis. They concluded that cirrhotics have decreased 
insulin sensitivity or endogenous insulin resistance that precedes impaired 
glucose tolerance and diabetes. 
                             A study was conducted in Italy by Nielson et al to find the 
pathogenesis of  glucose intolerance in liver cirrhosis. They found that 
endogenous glucose release suppression was unaltered but there was a 
defect in uptake of glucose
(52)
. There was a defect in glucose utilisation even 
during physiological conditions. They concluded that carbohydrate 
intolerance in cirrhosis is due to insulin resistance which can be ascribed to 
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defective glucose uptake rather than abnormalities in glucose production and 
beta cell function. 
                                        Reasons for insulin resistance in cirrhosis are 
proposed to be: 
 Insulin receptor/ post receptor defects 
 Increased pancreatic insulin secretion due to pancreatic beta cell 
hypertrophy 
 Elevated of insulin antagonists like cytokines, free fatty acids, 
glucagon, growth hormone and catecholamines  
 Downregulation of insulin receptors 
 Impaired removal of insulin by liver due to porto systemic shunting. 
 
INSULIN RESISTANCE AND HEPATITIS C VIRUS 
(49) 
 
                    Association of insulin resistance and HCV virus related 
cirrhosis was demonstrate by Allison et al., They found that HCV related 
cirrhosis developed diabetes more frequently than those of non HCV virus. 
Few cases have occurred even without cirrhosis
(49)
. Diabetes is associated 
with genotypes 1b, 2a and 4 and others may not develop insulin resistance. 
Similar insulin resistance was not present in hepatitis B implying hepatitis C 
virus has some role in causing diabetes. 
     The mechanisms proposed for insulin resistance in HCV virus are: 
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 STEATOSIS:   
            It is the accumulation of fat in hepatocytes. It is a major factor 
contributing to insulin resistance during liver diseases. It is described in 40- 
80% of patients with HCV related cirrhosis. Studies on mechanism of 
steatosis by HCV suggest that core protein inhibits microsomal triglyceride 
transfer protein activity and very low density lipoprotein secretion. It also 
impairs the expression of Peroxisome Proliferator-Activated Receptor. 
 Oxidative stress:  
                        It was noticed that HCV-core protein present within the outer 
membrane of mitochondria induces oxidation of mitochondrial glutathione 
and there is increased reactive oxygen species (ROS) production by 
mitochondrial electron transport complex I and III. 
                       Insulin resistance is maximally related to genotype C. It is 
found to be associated with reduced response rate to ribavirin and 
interferons and rapid progression to fibrosis. Thus insulin resistance has 
important implications in disease progression and treatment options. 
                       Pancreatic islet cell hypertrophy has been reported in biopsy 
of patients with liver cirrhosis. It is due to compensatory increase in beta 
cells to insulin resistance 
(52)
. Takei et al proposed that islets in cirrhosis 
show higher proliferation and lower apoptosis to those without disease. 
Insulin resistance associated with cirrhosis was significantly associated with 
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development of portal hypertension in initial stages but later after portal 
hypertension develops 
(53)
, HOMA 2 index rises due to porto collateral 
circulation. 
                       Insulin is proposed to stimulate endothelial NO production 
through phosphatidylinositol 3 kinase and serine threonine kinase signalling 
pathway 
(52)
. As a consequence of insulin resistance, reduced signalling and 
increased NO production results in endothelial dysfunction and therefore can 
lead to multiple cardiovascular events.  
                       The major causes of death in patients with insulin resistance 
and cirrhosis are complications of liver disease like chronic liver failure, 
gastrointestinal haemorrhage and hepatocellular carcinoma 
(53)
. Therefore 
the major aim in managing patients with hepatogenous diabetes include 
reducing complications of cirrhosis and the incidence of hepatocellular 
carcinoma. 
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ASSESSMENT OF INSULIN RESISTANCE: 
EUGLYCEMIC CLAMP 
(54)
:  
           It is the gold standard for diagnosing insulin resistance as it considers 
the dynamic change in glucose levels. The goal is to acutely raise the blood 
glucose to a fixed state of about 125 mg/dl from the base value. The priming 
dose is given for 15 minutes and then maintenance dose for every five 
minutes till the study is finished. Therefore a constant glucose level has to 
be maintained by adjusting the rate of infusion. 
             In this situation, insulin is infused constantly to maintain levels 
above 100mu/ml. So glucose infusion equals glucose uptake into tissues 
producing euglycemic state. This represents the body’s response to 
exogenous insulin. 
Advantages: 
 Helps to assess beta cell sensitivity and amount of glucose 
metabolised in response to hyperglycemic stimulus 
 Assessment of early pulsatile and late maintenance insulin release 
 Amount of glucose metabolised can be assessed 
 After insulin administration, due to continuous infusion of glucose 
role of counter regulatory hormones are prevented and we may know 
the true insulin sensitivity of the tissues 
 If labelled glucose is used, it may clearly give additional information 
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about site of clearance of insulin- liver vs periphery 
Disadvantages:  
 Time consuming 
 Expensive 
 Needs good laboratory setup  
 Can’t be easily repeated 
HOMA evaluation:                     
           The Homeostatic model assessment is a validated tool to measure 
insulin resistance using fasting insulin and triglycerides. The first and 
original model was proposed by Mattew et al in 1985 and it is been on 
constant use for epidemiological purpose also. Recently with few changes in 
physiological parameters it is upgraded to a computer version HOMA 2
(55-57)
 
.  
 HOMA1- 1R is calculated by the following formula: 
HOMA1 -1R= fasting insulin (ц U/dl) * fasting glucose (mmol/L). 
HOMA 2-IR is obtained through programmed HOMA calculator 
downloaded from The Oxford University for Diabetes, Endocrinology and 
Metabolism. Several studies suggest that HOMA 2 can be a useful tool to 
identify subjects with insulin resistance who are at risk of developing 
cardiovascular disease. 
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             Though defining cut off values for defining insulin resistance using 
HOMA scale is under various study, we have taken a study conducted by 
Bruno et al as the reference which gives 2.7 for HOMA 1R and 1.8 for 
HOMA2 IR for defining insulin resistance. 
TyG index
(58)
:  
               It is calculated using fasting glucose and fasting triglycerides. The 
formula is {ln (fasting triglycerides mg/dl)* fasting glucose mg/dl /2}. The 
cut off value is 4.6. 
               It is considered to be a mirror of gold standard euglycemic clamp 
in assessing insulin resistance and it has comparatively good sensitivity to 
HOMA 1 model though not superior to it. It can be effectively used 
epidemiologically for assessing insulin resistance when fasting insulin 
values are not available. But the major limitation it does not reflect the 
physiological changes of glucose and insulin. Although there is no clear 
correlation between insulin resistance and hypertriglyceridemia, it is 
proposed that elevated triglycerides in muscle impairs insulin sensitivity by 
altering muscle glucose metabolism. 
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QUICKI index: QUANTITATIVE INSULIN SENSITIVITY INDEX. 
It is a surrogate marker for HOMA scale to define insulin resistance 
which showed comparable results with HOMA. 
                QUICKI =1/{log( 𝐼°) + log (𝐺°)}  
where I
0
 is fasting insulin in mu/ml and G
0
 is fasting insulin in mg/dl.          
Since it is the reciprocal of log transformed product of insulin and glucose, it 
is a dimensionless number. It reflects only hepatic insulin sensitivity. 
 
LIPID PROFILE IN CIRRHOSIS  
.         Liver plays an important role in lipids and lipoprotein metabolism. 
Endogenous cholesterol synthesis from hepatic microsomes cause 
decrease in serum levels. Also HDL, LDL and apolipoprotein levels are 
reduced in cirrhosis. There were many studies previously conducted in 
various parts of world found that dyslipidemia is common in liver 
diseases like reduced cholesterol, HDL, LDL and TGL and suggested 
that cirrhosis  is a state of hypolipidemia
(59,60)
. Also in cirrhosis energy is 
derived mostly by lipolysis because energy utilisation from glucose 
through glucose oxidation is impaired. Furthermore, their adipose tissue 
and lipid metabolism are insensitive to insulin. Thus, it is a state of 
hypermetabolism  because energy expenditures are high due to increased 
utilisation of lipid stores.  
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                  Kackar et al. found that the serum cholesterol levels decreases 
progressively with the progress of alcoholic cirrhosis But there was an 
Indian study conducted in a north eastern teaching hospital showed elevated 
triglycerides and reduced LDL and total cholesterol occur in them. 
Previously it was found that serum triglycerides was higher in child class A 
than in child class B and C which is due to preserved ability for class A to 
synthesise VLDL than class B and C. 
 
TRIGLYCERIDES AND INSULIN RESISTANCE: 
                Skeletal muscle constitutes about 40 % of  body mass and 80% of 
glucose usage. Hence increased blood glucose in obesity and diabetes is 
associated with insulin resistance in skeletal muscle. Lipids are found to be 
the source of energy since the end of 1950. There is a critical link between 
muscle triglycerides and insulin sensitivity. Increased muscle triglycerides 
observed in obese and diabetes are linked with decreased insulin sensitivity. 
Hence excess lipid and lipid metabolites accumulation in the muscle are 
significantly associated with insulin resistance. 
                 In this study, we have tried to find any relation of triglycerides 
with insulin resistance in cirrhosis. 
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MATERIALS AND METHODS 
                      This study was conducted in Government Royapettah hospital 
for a duration of 1 year from July 2014 to July 2015. The study was 
conducted after getting informed consent from all the patients involved in 
this study. Ethical committee clearance was obtained from Kilpauk Medical 
College. 
STUDY DESIGN: It was designed as cross sectional study 
STUDY POPULATION: 50 
INCLUSION CRITERIA:     
                              Patients with cirrhosis already proven by imaging who 
attends Medicine  and Medical Gastroenterology outpatient clinic and 
inpatients in medical wards. 
EXCLUSION CRITERIA: 
1. Diabetes mellitus as defined by ADA with fasting blood glucose >126 
mg/dl 
2. Hepatitis C virus infection 
3. Pregnancy 
4. Lactation 
5. Cardiac failure 
6. Renal failure 
65 
 
7. Respiratory failure 
8. Hepatocellular carcinoma 
9. Presence of infection and  acute decompensation in the prior 2 wk; 
10. Prescription of  hypolipidemic drugs , antihypertensives, 
corticosteroid, bronchodilator , vasoactive, or hypoglycemic agents 
within 1 month. 
METHODOLOGY: 
                                       Patients who were already diagnosed to have 
cirrhosis and attending medical or medical gastroenterology outpatient 
clinics and inpatients in medical ward were taken into study. The sample 
size was set to be 50. A detailed clinical examination was performed. Height 
and weight were measured. Presence of ascites and pedal edema were noted. 
After getting consent from the patients following investigations were done: 
1.Fasting insulin 
2.Fasting blood glucose 
3.Fasting serum triglyceride 
4. Blood urea, Serum creatinine. 
6.Liver function tests- bilirubin, AST,ALT, ALP, serum total protein, serum 
albumin 
7. Prothrombin Time/ International Normalised Ratio (INR) 
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8.Ultrasound abdomen 
BODY MASS INDEX: 
Body mass index was calculated using the formula weight ( kg)/ height* 
height(m). If ascites was present, then correction of 4 was given for weight. 
INSULIN RESISTANCE: 
HOMA 1R:  
 {fasting insulin (ц U/dl) * fasting glucose ( mmol/L)}/22.5. 
 A value >2.7 is taken as insulin resistance. 
HOMA2R:  
 Programmed calculator downloaded from university of oxford. 
http://www.dtu.ox.ac.uk/. Value of  >1.8 is taken as insulin resistance. 
TyG INDEX:  
 The formula is { ln ( fasting triglycerides mg/dl)* fasting glucose (mg/dl) 
/2} . The cut off value is 4.6. 
TRIGLYCERIDE LEVELS:  
  Fasting triglycerides were seen after 8 hours of overnight fasting. 
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Normal: Less than 150 mg/Dl 
Borderline High: 150 - 199 mg/dL 
High: 200 - 499 mg/dl 
Very High: 500 mg/dL or above 
RESULTS AND STATISTICAL ANALYSIS 
                             The data obtained was analysed using SSPS software. Chi 
square test was used for comparison of dichotomous variables. A p value of 
<0.05 was taken as statistically significant value. Pearson correlation 
coefficient was used to compare the regression coefficient between two 
groups. 
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RESULTS 
AGE DISTRIBUTION: 
 
S no Age  Frequency  Percent % 
1 30-40 16 32 
2 41-50 18 36 
3 51-60 13 26 
4 >60 3 6 
 
 
 This table shows age distribution of our study population. 
 
AGE IN YEARS: 
 
 
Pie chart representing age distribution of patients in numbers 
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 In this study about 18 patients in the age group 41-50 years are major 
contributors. All the patients are more than 30 years and maximum age in our 
study is 75 and minimum is 31.The mean age of study population is 46.18 ± 
9.78 years. 
 
SEX DISTRIBUTION: 
 
Pie chart showing sex distribution in our study in numbers. 
Out of fifty cases, 47 cases are male and only 3 are female. 
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HOMA 1R: 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
P value 
IR - 33 66.0 66.0 66.0  
0.024 
IR + 17 34.0 34.0 100.0 
Total 50 100.0 100.0   
 This table shows number and percentage of our study group showing 
insulin resistance according to HOMA1 IR and statistical significance 
 
 
Pie chart showing distribution of insulin resistance as per HOMA 1R score. 
Number of patients are shown.  
 
 
17 
33 
IR +
IR -
72 
 
                           In our study, 17 patients out of 50 had insulin resistance by 
HOMA 1 which accounts for 34 % of patients which is statistically significant 
with p value < 0.001. 
 
 
Bar diagram showing age wise distribution of IR by HOMA 1. 
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AGE VS HOMA 1R 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this table, age wise distribution of presence and absence of insulin 
resistance is shown according to HOMA1 IR. 
      According to HOMA 1- IR calculated , in our study 17 patients had insulin 
resistance which comes to about 34%.  Out of 17 patients who had insulin 
resistance, 3 patients (17.6%) were in the age group of  30-40 years, 8 patients 
Age in years 
  
  
HOMA 1R 
Total NO IR IR + 
30-40 
  
  
Count 13 3 16 
% within HOMA 
1R 
39.4% 17.6% 32.0% 
41-50 
  
  
Count 10 8 18 
% within HOMA 
1R 
30.3% 47.1% 36.0% 
51-60 
  
  
Count 9 4 13 
% within HOMA 
1R 
27.3% 23.5% 26.0% 
Above 60 
  
  
Count 1 2 3 
% within HOMA 
1R 
3.0% 11.8% 6.0% 
Total 
 
 
 
Count 33 17 50 
% within Age in 
years 
66.0% 34.0% 100.0% 
% within HOMA 
1R 
100.0% 100.0% 100.0% 
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(47.1%) were in 41-50 years, 4patients (23.5%) were in 51-60 years and 2 
patients (11.8%) were in more than 60 years age group. 
 HOMA 2: 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
P value 
IR - 
36 72.0 72.0 72.0 
 
0.002 
IR + 
14 28.0 28.0 100.0 
Total 
50 100.0 100.0   
 
This table shows number and percentage of our study group showing 
insulin resistance according to HOMA2 IR score.  
 
In this pie chart, number of patients showing insulin resistance according 
to HOMA 2 is shown. 
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In this study, out of 50 patients 14 patients (28%) had insulin resistance 
according to HOMA 2 IR score. It was statistically significant with p value of  
0.002 ( < 0.05). 
 
 
 
Bar diagram showing age distribution of IR by HOMA2 IR 
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HOMA 2 IR VS AGE 
Age in years 
  
  
HOMA 2 Total 
  No Problem Problem 
30-40 
  
Count 13 3 16 
%within 
HOMA 2 
36.1% 21.4% 32.0% 
41-50 
  
Count 10 8 18 
% within 
HOMA 2 
27.8% 57.1% 36.0% 
51-60 
  
Count 10 3 13 
% within 
HOMA 2 
27.8% 21.4% 26.0% 
Above 60 
  
Count 3 0 3 
% within 
HOMA 2 
8.3% .0% 6.0% 
Total Count 36 14 50 
% within Age 
in years 
72.0% 28.0% 100.0% 
% within 
HOMA 2 
100.0% 100.0% 100.0% 
 
In this chart, we can see age wise distribution of presence of insulin 
resistance is shown. 
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In our study, out of 50 patients, 14 patients have insulin resistance which comes 
to around  28%. Out of 14 patients , 3 patients(21.4%) were in age group 30-40 
years, 8 patients( 57.1%) in 41-50 years group, 3 patients (21.4%) in 51- 60 
years age group  and no one were above 60 years group. 
 
FASTING TRIGLYCERIDES: 
 
 
This pie chart shows triglyceride levels in our study group 
In our study, out of 50 patients only two patients  had fasting triglyceride values 
> 150 mg/dl, with majority had values < 100 mg/dl.  
 
 
2 
48 
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TGL 
>150
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CHILD TURCOTT PUGH SCORE (CTP): 
 
 This pie chart depicts patients in numbers in three different child class. 
In this study, out of fifty patients taken in to study, 18 were in CTP A, 19 in B 
and 13 in CTP C score.  
 
Bar diagram showing age wise distribution of  patients in CTP score  
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CTP VS AGE 
Age in years 
  
  
  
CTP Total 
  A B C 
30-40 
  
  
Count 7 7 2 16 
% within CTP 
38.9% 36.8% 15.4% 32.0% 
  
41-50 
  
  
Count 4 6 8 18 
% within CTP 
22.2% 31.6% 61.5% 36.0% 
  
51-60 
  
  
Count 7 3 3 13 
% within CTP 
38.9% 15.8% 23.1% 26.0% 
  
Above 60 
  
  
Count 0 3 0 3 
% within CTP 
.0% 15.8% .0% 6.0% 
Total 
  
  
Count 18 19 13 50 
% within Age 
in years 
36.0% 38.0% 26.0% 100.0% 
% within CTP 100.0% 100.0% 100.0% 100.0% 
 
This chart shows age wise distribution of all three class of patients 
In CTP A , out of 18 patients 7 were in the age group pf 30- 40 years, 4 patients 
were in 41-50 years age group, 7 patients were in 51- 60 years age group and no 
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one in > 60 years. In CTP B, out of 19 patients 7 were in 30 -40 years age 
group, 6 in 41-50 years group, 3 in 51- 60 years and 3 in more than 60 years. In 
CTP C, out of 13 patients 2 were in 30-40 age group, 8 were in 41- 50 years age 
group and 3 in 51- 60 years age group. 
HOMA AND CTP COORELATION: 
 
HOMA 1R 
  
  
CTP 
Total 
  
P value 
A B C 
 
 
 IR - 
  
  
Count 17 15 1 33  
 
 
 
 
 
 
<0.001*
* 
% within 
HOMA 1R 
51.5% 45.5% 3.0% 100.0% 
% within 
CTP 
94.4% 78.9% 7.7% 66.0% 
 
 
 IR + 
  
Count 1 4 12 17 
% within 
HOMA 1R 
5.9% 23.5% 70.6% 100.0% 
% within 
CTP 
5.6% 21.1% 92.3% 34.0% 
 Total Count 18 19 13 50 
% within 
HOMA 1R 
36.0% 38.0% 26.0% 100.0% 
% within 
CTP 
100.0% 100.0% 100.0% 100.0% 
This table compares insulin resistance by HOMA1  with CTP score. 
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By HOMA1- IR, among 18 CTP A patients, 1 had insulin resistance, 
among 19 CTP B patients, 4 had insulin resistance and among 13 CTP C 
patients, 12 had insulin resistance. As the CTP grade increases, insulin 
resistance among the patients increases which was statistically significant (p 
value <0.001). 
HOMA 2-IR AND CTP CORRELATION: 
 
 HOMA 2 
  
  
CTP Total 
  
P value 
A B C 
IR - 
  
  
  
  
Count 17 18 1 36  
 
 
 
 
 
<0.001 
% within 
HOMA 2 
47.2% 50.0% 2.8% 100.0% 
% within CTP 
94.4% 94.7% 7.7% 72.0% 
  
IR + 
  
  
  
  
Count 1 1 12 14 
% within 
HOMA 2 
7.1% 7.1% 85.7% 100.0% 
% within CTP 
5.6% 5.3% 92.3% 28.0% 
Total 
  
  
Count 18 19 13 50 
% within 
HOMA 2 
36.0% 38.0% 26.0% 100.0% 
% within CTP 100.0% 100.0% 100.0% 100.0% 
This table compares insulin resistance by HOMA2 with CTP score. 
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Out of 18 patients in CTP A score, only 1 had insulin resistance according 
to HOMA 2-IR and out of 19 patients in CTP B score 1 had insulin resistance 
and out of 13 patients in CTP C score, 12 had insulin resistance. It was found to 
be statistically very significant p<0.001. 
CORRELATION WITH HOMA 1- 1R: 
 
  Pearson 
cooefficient 
P value 
BMI HOMA1-IR 0.422 0.002 
 
FBS HOMA1-IR 0.461 
0.001 
Fasting TGL HOMA1-IR -0.144  
0.320 
 
Fasting Insulin 
(Microgm/dl) 
HOMA1-IR 0.968  
<0.001 
 
 
This table shows correlation of HOMA1 IR with parameters like BMI, 
fasting insulin, glucose and triglycerides. 
There is a positive correlation between insulin resistance and BMI, fasting 
blood sugar and fasting insulin by HOMA1 IR. There is no correlation between 
triglycerides and HOMA 1 I 
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CORRELATION WITH HOMA 2 IR: 
 
    
Pearson 
coefficient P value 
BMI 
  
  
HOMA 2 
0.422 0.002 
FBS  
  
  
HOMA 2 
0.351 0.013 
Fasting TGL 
  
  
HOMA 2 
-0.101 0.485 
Fasting Insulin 
(Microgram/dl) 
  
  
HOMA 2 
0.935 <0.001 
 
This table shows correlation of HOMA2 IR with parameters like BMI, 
fasting insulin, glucose and triglycerides. 
There is positive correlation between HOMA2 IR and BMI, fasting glucose and 
fasting insulin. There is no correlation between fasting triglyceride and insulin 
resistance by HOMA2 IR score.  
 TyG index: 
All the 50 patients had TyG index < 4.68 in our study. 
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BASELINE DESCRIPTIVE CHARACTERISTICS OF THE STUDY 
GROUP: 
 
 N Minimum Maximum Mean Std. Deviation 
Age in years 
50 30 75 46.18 9.78 
BMI 
50 15.79 46.25 22.13 5.09 
FBS 
50 60 126 100.10 27.77 
FBS MMOL/L 
50 3.3 9.60 5.56 1.54 
Fasting TGL 
50 56 172 89.36 26.30 
Fasting Insulin 
(Microgm/dl) 50 3.00 58.09 12.41 11.60 
HOMA 1R 
50 .50 16.78 3.27 3.50 
HOMA 2 
50 .4 7.3 1.53 1.28 
TyG index 
50 3.3 4.0 3.61 .172 
Valid N 
(listwise) 
50      
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DISCUSSION 
Diabetes can lead to non alcoholic fatty liver disease and non alcoholic 
steatohepatitis and ultimately cirrhosis. But conversely cirrhosis can lead to 
impaired glucose tolerance and diabetes. Diabetes occurring in the setting of 
cirrhosis is called hepatogenous diabetes. Hepatogenous diabetes has little micro 
and macrovascular complications 
(61)
. The present study was conducted to know 
whether cirrhosis is an insulin resistant state  or not because in future it may lead 
to  impaired glucose tolerance and frank diabetes. 
AGE: 
The mean age of our study population is 46.18 years and majority are in 
the age group of  41- 50 years. According to study conducted by Mukherjee et al 
from Calcutta National Medical College, the mean age of cirrhotic population 
was 44 ± 10.2 years
(62)
.  A study conducted by Goswami et al from Jodhpur 
found the mean age of cirrhotic population was 52.3 ± 13.7 years 
(63)
. There was 
a cross sectional study conducted in a teaching hospital in Assam by 
Jyotiprakash et al to find the lipid profile abnormalities in alcoholic cirrhosis 
showed mean age group of alcoholic cirrhosis was 41- 50 years 
(64)
. According 
to Doud’s et al, the mean age of alcoholic cirrhosis in south Asian male was 44 
years
(65)
. 
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SEX: 
According to our study, cirrhosis of liver was common among male 
population with male female ratio of 15:1. A study by Bhargava et al, the male 
female ratio was found as 6:1. Another study by Sarkar et al., also showed that 
86% of cases of cirrhosis were males and 14% were females. The male 
preponderence of cirrhosis in South India is due to its etiology alcohol which is 
more common in males 
(66,)
. In Western population the most common cause of 
cirrhosis is due to HCV because of high prevelance of intravenous drug abuse 
(14). A study by Sinha et al., found that 99 % of cirrhotics in their study were 
male. The Dionysos study group found a male: Female ratio of 9:1 in alcoholic 
cirrhosis
(67)
 .  
 
CHILD TURCOTT PUGH SCORE (CTP): 
                                     In our study, majority of patients are in CTP B ( 38%) 
followed by CTP A( 36%). 
  In our study, we used three scores to assess insulin resistance and then 
association of insulin resistance with serum triglycerides was assessed. We took 
the reference values according to Bruno Geloneze et al ,where  the cut off value 
for diagnosing insulin resistance using  HOMA1 was  >2.7 and  using HOMA 2 
IR it was > 1.8 
(68)
. 
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HOMA 1-1R: 
                              In our study, insulin resistance by HOMA-1 IR was present 
in 17 patients out of 50, which constitutes  about 34 % which is statistically 
significant ( p value < 0.05). The common age group showing insulin resistance 
by HOMA1-IR in our study is 41-50 years (36%) followed by 30 - 40 years ( 
32%). 
HOMA2 IR: 
     Insulin resistance was found in 14 patients out of 50 by HOMA 2 
contributing to 28% which is statistically highly significant (p value 0.002). The 
common age group showing insulin resistance by HOMA 2 in our study is 41- 
50 years ( 36%) followed by 30-40 years (32%). 
                       There was a study conducted by Goswami. et. Al from Jodhpur, 
India which showed that insulin resistance was present in 68.5% of euglycemic 
cirrhotics and universally present in all cirrhotics with recent diabetes. 
                              A study conducted in Spain by Eva Erice et al on insulin 
resistance in patients with cirrhosis and portal hypertension showed that insulin 
resistance was present in 60 % of the study population. Insulin resistance in this 
group was assessed by HOMA 2 index. They concluded that IR prevalence 
might increase upto 70 % if the patients had concomitant portal hypertension 
with HVPG > 10mmHg
(69)
. 
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                                     A cross sectional study done in Kolkata by Mukherjee 
et.al showed the prevalence of impaired glucose tolerance is estimated to about 
60- 80 % and overt diabetes in 7- 15%
(70)
 . In that study, about 74 % of cirrhosis 
was due to alcohol, 14 % was due to hepatitis C virus and 2.9 % was due to 
autoimmune hepatitis. This study also showed IGT and diabetes were frequently 
higher in patients aged >45 years. But etiology had not influenced IGT and 
diabetes according to their study. 
                                          A study conducted by Bonora et al showed inverse 
correlation between clamp mediated glucose disposal and HOMA estimated 
insulin sensitivity. They also validated the study for use in large epidemiological 
purposes 
(71)
. A study conducted by Fernando. et al from Mexico showed TyG 
index and HOMA were almost similar in assessing IR. But in our study, even  
patients who showed insulin resistance by HOMA 1 and HOMA 2 index, failed 
to show values above the cut off for TyG index which was taken as 4.6. 
                                          As liver is the hub of major lipid synthesis and 
metabolism, dearrangements in lipid profile can be expected in liver cirrhosis. 
According to Jyotiprakash et al, study from north eastern India, they concluded  
that serum total cholesterol values are lowered in alcoholic cirrhotic patients 
compared with the normal, healthy individuals. The serum HDL cholesterol and 
LDL cholesterol levels are also significantly decreased compared with the 
normal controls but serum triglycerides were significantly increased in cases 
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than controls.  Kackar et al. found that the serum cholesterol levels decreases 
progressively with the progress of alcoholic cirrhosis
(72). 
              In a Nigerian study, the median total cholesterol and HDL 
cholesterol levels were significantly higher in controls compared with cirrhotic 
patients; however, LDL cholesterol levels were higher in controls compared 
with cirrhotic patients and the difference was not statistically significant.
 
However, alcoholic cirrhosis may be associated with increased total cholesterol 
and LDL cholesterol levels, as found by Varghese et al 
(73)
.Another Indian study 
showed elevated triglycerides with decreased serum cholesterol in cirrhosis 
(74)
. 
                                          In our study, we found that serum triglycerides were 
not elevated and so TyG index which is calculated based on triglycerides and 
fasting glucose failed to detect IR in those who are detected by HOMA model. 
INSULIN RESISTANCE AND CTP: 
                                      Insulin resistance was found mostly in CTP C patients  
by both HOMA 1IR and HOMA2 IR which contributed to about 92 % and 
92.3% of  cases with HOMA 1 IR and HOMA 2 IR respectively. This is 
consistent with study from Jodhpur, India by Goswami & Bargava et al where 
they showed  significant increase in insulin resistance in patients with CTP> 10 
and MELD > 15. However, another Indian study by Mukherjee et al from 
Calcutta showed no correlation with CTP score or with duration of illness 
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CONCLUSIONS 
 The majority of patients with cirrhosis in our study are in the age group of 
41- 50 years. 
 About 94% of patients included are males. 
 Majority of population included are in CTP B followed by CTP C. 
 Insulin resistance is found in 34 % of patients using HOMA 1IR and 28% 
of patients using HOMA 2 IR. 
 TyG index failed to show insulin resistance in those shown by HOMA 
model. 
 Serum triglyceride levels are not elevated in our study population. 
 Insulin resistance is significantly higher in patients with CTP C by both 
HOMA 1 and HOMA 2. 
 Advancement of liver disease as indicated by CTP C shows increase in 
insulin resistance and compensatory increase in pancreatic beta cell 
function as indicated by HOMA 2 
 Insulin resistance demonstrated in these euglycemic cirrhotics has no 
correlation with serum triglyceride levels. 
 So, occurrence of impaired glucose tolerance and diabetes is a major 
concern in these patients which could definitely have bearing upon 
treatment strategy as they have increased risk of deaths related to 
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complications of liver cirrhosis like gastrointestinal haemorrhage and 
hepatocellular carcinoma. 
Finally to conclude, cirrhosis of liver is an insulin resistant state and 
insulin resistance in these euglycemic cirrhotics is not related to serum 
triglyceride levels. 
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LIMITATIONS OF THE STUDY 
 Very small sample size 
 Duration of cirrhosis is not considered. 
 Insulin resistance with respect to different etiologies are not 
considered. 
 Relationship with sex and insulin resistance could not be assessed 
due to small number of female patients included in our study. 
 Vitamin D levels were not assessed as decrease in their levels 
increase insulin resistance in cirrhosis. 
 For some patients previous records could not be obtained about 
glycemic status. 
 Further follow up of patients were not done, hence further 
assessment of glycemic status could not be done. 
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ANNEXURES 
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PROFORMA 
 
NAME:       
AGE:   
SEX: 
ADDRESS:        
 
HISTORY: 
h/o Any drug intake in prior two weeks 
h/o Any respiratory illness 
h/o Alcohol intake 
h/o Previous blood transfusion, tattooing, iv drug abuse 
h/o TPN 
GENERAL EXAMINATION 
Height: 
Weight: 
CVS: 
RS: 
P/A: 
CNS: 
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INVESTIGATION 
 
1. Blood glucose –fasting 
2. Fasting serum triglycerides 
3. Fasting insulin levels 
4. Blood urea, serum creatinine 
5. Liver function test with enzymes 
6. Ultrasonogram 
7. HBsAg, Anti-HCV 
 
 
 
 
 
 
 
 
 
 
SIGNATURE OF INVESTIGATOR            
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AuØPõÚ ÂÍUP[PøÍ²® öuÎÄ£kzvU öPõs÷hß. 
 
2. ÷©¾® C¢u Bµõ´a]US GÚx ö\õ¢u Â¸¨£zvß ÷£¶À £[÷PØQ÷Óß 
GßÖ®, ÷©¾® G¢u ÷{µzv¾® GÆÂu ¬ßÚÔÂ¨¦ªßÔ C¢u 
Bµõ´a]°¼¸¢x Â»P ¬Êø©¯õÚ E¶ø© EÒÍøu²®, CuØS GÆÂu 
\mh ¤øn¨¦® CÀø» Gß£øu²® AÔ÷Áß. 
 
3. Bµõ´a]¯õÍ÷µõ, Bµõ´a] EuÂ¯õÍ÷µõ, Bµõ´a] E£¯zuõ÷µõ, Bµõ´a] 
÷£µõ]¶¯÷µõ, KÊ[Sö{Ô ö\¯ØSÊ EÖ¨¤ÚºP÷Íõ G¨÷£õx 
÷Ásk©õÚõ¾® GÚx AÝ©v°ßÔ GÚx EÒ÷{õ¯õÎ £vÄPøÍ C¢u 
Bµõ´a]UPõP÷Áõ AÀ»x GvºPõ» ¤Ó Bµõ´a]PÐUPõP÷Áõ 
£¯ß£kzvUöPõÒÍ»õ® GßÖ® ÷©¾® C¢u |£¢uøÚ {õß 
CÆÁµõ´a]°¼¸¢x Â»QÚõ¾® uS® GßÖ® J¨¦UöPõÒQ÷Óß. B°Ý® 
GÚx Aøh¯õÍ® \®£¢u¨£mh G¢u £vÄPÐ® (\mh§ºÁ©õÚ ÷uøÁPÒ 
uÂµ) öÁÎ°h¨£h©õmhx GßÓ EÖvö©õÈ°ß ö£¯¶À C¢u 
Bµõ´a]°¼¸¢x QøhUP¨ö£Ö® ¬iÄPøÍ öÁÎ°h ©Ö¨¦ 
öuÔÂUP©õm÷hß GßÖ EÖv¯ÎUQß÷Óß. 
 
   
4. C¢u Bµõ´a]US {õß ¬Ê©Úxhß \®©vUQß÷Óß GßÖ® ÷©¾® 
Bµõ´a]U SÊÂÚº GÚUS AÎUS® AÔÄøµPøÍ uÁÓõx ¤ß£ØÖ÷Áß 
GßÖ® EÖv¯ÎUQß÷Óß. 
 
5. C¢u Bµõ´a]USz ÷uøÁ¨£k® AøÚzx ©¸zxÁ¨ £¶÷\õuøÚPÐUS® 
JzxøÇ¨¦ u¸÷Áß GßÖ EÖv¯ÎUQß÷Óß. 
 
 6. C¢u Bµõ´a]US ¯õ¸øh¯ ÁØ¦Özu¾ªßÔ GÚx ö\õ¢u Â¸¨£zvß 
÷£¶¾® _¯AÔÄhÝ® ¬Ê©ÚxhÝ® \®©zvUQß÷Óß GßÖ Cuß -»® 
J¨¦UöPõÒQ÷Óß. 
 
÷{õ¯õÎ°ß øPö¯õ¨£® / ö£¸ÂµÀ øP÷µøP 
Ch®:     ÷uv: 
Bµõ´a]¯õÍ¶ß øPö¯õ¨£® 
Ch®:     ÷uv: 
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